Skip to main content

Efficacy and Safety Limitations of Attention-Deficit Hyperactivity Disorder Pharmacotherapy in Children and Adults

CNS Drugs volume 23, pages 21–31 (2009)Cite this article

Abstract

There have been major advances in the treatment and understanding of attention-deficit hyperactivity disorder (ADHD) in the last decade. Among these are the availability of newer stimulant formulations, an appreciation of the combined effects of medication and behavioural therapies, and a better understanding of the neurobiology of the disorder in children (aged 6–12 years), adolescents and adults. This article focuses on the evaluation of the efficacy and safety profiles of medications used for the management of ADHD.

In assessing the various medical treatments for ADHD, certain issues and analyses have become important to address. The diagnosis, characterization and quantification of ADHD symptoms are crucial to assessing treatment effectiveness. A standardized setting for measuring the severity of ADHD symptoms is the laboratory school protocol, which simulates a school environment with tightly controlled timing of measurements. This method has been adapted successfully to the adult workplace environment to help with the evaluation of adult ADHD symptoms.

Statistical analyses, such as effect size and number needed to treat, may aid in the comparison and interpretation of ADHD study results. Although an objective approach to evaluating the efficacy and safety profiles of the available medications provides necessary details about the medical options, typical clinical decisions are often based on trial and error and may be individualized based on a patient’s daily routine, comorbidities and risk factors.

Stimulants remain the US FDA-approved medical treatment of choice for patients with ADHD and are associated with an exceptional response rate. Findings of the Multimodal Treatment of Children With ADHD study suggest that the combination of behavioural and medical therapy may benefit most patients. Nonstimulant agents, such as atomoxetine (FDA-approved), and several non-approved agents, bupropion, guanfacine and clonidine, may offer necessary alternatives to the stimulants. This is especially important for patients who have comorbidities that are contraindicated for stimulant use based on medical issues and/or risk for stimulant abuse. Typical psychiatric comorbidities in patients with ADHD include oppositional defiant disorder, conduct disorder, major depressive disorder, bipolar disorder, anxiety, substance abuse disorder, tic disorder, and Tourette’s syndrome.

Although relatively safe, both stimulants and atomoxetine have class-related warnings and contraindications and are associated with adverse effects that require consideration when prescribing. Polypharmacy is a common psychiatric approach to address multiple symptoms or emergent adverse effects of necessary treatments. Future research may provide an improved understanding of polypharmacy and better characterization of the factors that influence the diagnosis and successful treatment of patients with ADHD.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Table I
Fig. 1
Fig. 2
Table II

References

  1. Bradley C. The behaviour of children receiving benzedrine. Am J Psychiatry 1937; 94: 577–85

    Google Scholar 

  2. Pelham WE, Aronoff HR, Midlam JK, et al. A comparison of Ritalin and Adderall: efficacy and time-course in children with attention-deficit/hyperactivity disorder. Pediatrics 1999; 103: e43

    CAS  PubMed  Google Scholar 

  3. Stein MA. Innovations in attention-deficit/hyperactivity disorder pharmacotherapy: long-acting stimulant and nonstimulant treatments. Am J Manag Care 2004; 10: S89–98

    PubMed  Google Scholar 

  4. Weisler RH. Review of long-acting stimulants in the treatment of attention deficit hyperactivity disorder. Expert Opin Pharmacother 2007; 8: 745–58

    CAS  PubMed  Google Scholar 

  5. Wigal SB, Wigal TL. The laboratory school protocol: its origin, use, and new applications. J Atten Disord 2006; 10: 92–111

    PubMed  Google Scholar 

  6. Swanson JM, Lerner M, Wigal T, et al. The use of a laboratory school protocol to evaluate concepts about efficacy and side effects of new formulations of stimulant medications. J Atten Disord 2002; 6Suppl. 1: S73–88

    PubMed  Google Scholar 

  7. Wigal SB, Gupta S, Guinta D, et al. Reliability and validity of the SKAMP rating scale in a laboratory school setting. Psychopharmacol Bull 1998; 34: 47–53

    CAS  PubMed  Google Scholar 

  8. Wigal T, Wigal S, Steinhoff K, et al. Establishing a clinical diagnosis of ADHD in adults: the QUEST method. Advances in ADHD 2007; 2: 17–24

    Google Scholar 

  9. Becker LA. Effect size [online]. Available from URL: http://web.uccs.edu/lbecker/Psy590/es.htm [Accessed 2009 Feb 9]

  10. Faraone SV, Sergeant J, Gillberg C, et al. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2003; 2: 104–13

    PubMed  PubMed Central  Google Scholar 

  11. Owens EB, Hinshaw SP, Kraemer HC, et al. Which treatment for whom for ADHD? Moderators of treatment response in the MTA. J Consult Clin Psychol 2003; 71: 540–52

    PubMed  Google Scholar 

  12. Stein MA, McGough JJ. The pharmacogenomic era: promise for personalizing attention deficit hyperactivity disorder therapy. Child Adolesc Psychiatr Clin N Am 2008; 17: 475–90

    PubMed  PubMed Central  Google Scholar 

  13. Van der Oord S, Prins PJ, Oosterlaan J, et al. Treatment of attention deficit hyperactivity disorder in children: predictors of treatment outcome. Eur Child Adolesc Psychiatry 2008; 17: 73–81

    PubMed  Google Scholar 

  14. Biederman J, Krishnan S, Zhang Y, et al. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther 2007; 29: 450–63

    CAS  PubMed  Google Scholar 

  15. Greenhill LL, Findling RL, Swanson JM. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2002; 109: e39

    PubMed  Google Scholar 

  16. Greenhill LL, Muniz R, Ball RR, et al. Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006; 45: 817–23

    PubMed  Google Scholar 

  17. Markowitz JS, Straughn AB, Patrick KS. Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations. Pharmacotherapy 2003; 23: 1281–99

    CAS  PubMed  Google Scholar 

  18. McCracken JT, Biederman J, Greenhill LL, et al. Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD. J Am Acad Child Adolesc Psychiatry 2003; 42: 673–83

    PubMed  Google Scholar 

  19. McGough JJ, Wigal SB, Abikoff H, et al. A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD. J Atten Disord 2006; 9: 476–85

    PubMed  Google Scholar 

  20. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001; 108: e83

    CAS  PubMed  Google Scholar 

  21. Wolraich ML, Greenhill LL, Pelham W, et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics 2001; 108: 883–92

    CAS  PubMed  Google Scholar 

  22. Elia J, Borcherding BG, Rapoport JL, et al. Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true nonresponders? Psychiatry Res 1991; 36: 141–55

    CAS  PubMed  Google Scholar 

  23. Scottish Intercollegiate Guidelines Network. Attention deficit and hyperkinetic disorders in children and young people: a national clinical guideline. Edinburgh, Scotland: SIGN Executive, 2001

    Google Scholar 

  24. Spencer T, Biederman J, Wilens T, et al. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 1996; 35: 409–32

    CAS  PubMed  Google Scholar 

  25. Swanson J, Wigal S, Wigal T, et al. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (The COMACS Study). Pediatrics 2004; 113: 206–16

    Google Scholar 

  26. Wigal SB, Wigal TL, Kollins SH. Advances in methylphenidate drug delivery systems for ADHD therapy. Advances in ADHD 2006; 1: 4–7

    Google Scholar 

  27. Spencer TJ, Wilens TE, Biederman J, et al. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/ hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006; 28: 266–79

    CAS  PubMed  Google Scholar 

  28. Faraone SV. Understanding the effect size of ADHD medications: implications for clinical care [online]. Available from URL: http://www.medscape.com/viewarticle/461543 [Accessed 2009 Feb 9]

  29. The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/ hyperactivity disorder. Arch Gen Psychiatry 1999; 56: 1073–86

    Google Scholar 

  30. Jensen PS, Garcia JA, Glied S, et al. Cost-effectiveness of ADHD treatments: findings from the multimodal treatment study of children with ADHD. Am J Psychiatry 2005; 162: 1628–36

    PubMed  Google Scholar 

  31. Swanson JM, Kraemer HC, Hinshaw SP, et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry 2001; 40: 168–79

    CAS  PubMed  Google Scholar 

  32. The MTA Cooperative Group. Moderators and mediators of treatment response for children with attention-deficit/ hyperactivity disorder: the multimodal treatment study of children with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999; 56: 1088–96

    Google Scholar 

  33. Jensen PS, Arnold LE, Swanson JM, et al. 3-year follow-up of the NIMH MTA study. J Am Acad Child Adolesc Psychiatry 2007; 46: 989–1002

    PubMed  Google Scholar 

  34. Mohammadi MR, Akhondzadeh S. Pharmacotherapy of attention-deficit/hyperactivity disorder: nonstimulant medication approaches. Expert Rev Neurother 2007; 7: 195–201

    CAS  PubMed  Google Scholar 

  35. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet 2005; 366: 237–48

    PubMed  Google Scholar 

  36. Banaschewski T, Roessner V, Dittmann RW, et al. Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry 2004; 13Suppl. 1: I102–16

    PubMed  Google Scholar 

  37. Wigal SB, McGough JJ, McCracken JT, et al. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. J Atten Disord 2005; 9: 275–89

    PubMed  Google Scholar 

  38. Greenhill LL, Newcorn JH, Gao H, et al. Effect of two different methods of initiating atomoxetine on the adverse event profile of atomoxetine. J Am Acad Child Adolesc Psychiatry 2007; 46: 566–72

    PubMed  Google Scholar 

  39. Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2008; 121: e73–84

    PubMed  Google Scholar 

  40. Connor DF, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1999; 38: 1551–9

    CAS  PubMed  Google Scholar 

  41. Daviss WB, Bentivoglio P, Racusin R, et al. Bupropion sustained release in adolescents with comorbid attention-deficit/hyperactivity disorder and depression. J Am Acad Child Adolesc Psychiatry 2001; 40: 307–14

    CAS  PubMed  Google Scholar 

  42. Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001; 158: 1067–74

    CAS  PubMed  Google Scholar 

  43. Wigal SB, Biederman J, Swanson JM, et al. Efficacy and safety of modafinil film-coated tablets in children and adolescents with or without prior stimulant treatment for attention-deficit/hyperactivity disorder: pooled analysis of 3 randomized, double-blind, placebo-controlled studies. Prim Care Companion J Clin Psychiatry 2006; 8: 352–60

    PubMed  PubMed Central  Google Scholar 

  44. Palumbo DR, Sallee FR, Pelham Jr WE, et al. Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry 2008; 47: 180–8

    PubMed  Google Scholar 

  45. Arnsten AFT. Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: an important role for prefrontal cortex dysfunction. CNS Drugs 2009; 23Suppl. 1: 33–41

    CAS  PubMed  Google Scholar 

  46. Scahill L. Alpha-2 Adrenergic agonists in children with inattention, hyperactivity and impulsiveness. CNS Drugs 2009; 23Suppl. 1: 43–49

    CAS  PubMed  Google Scholar 

  47. Biederman J, Swanson JM, Wigal SB, et al. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics 2005; 116: e777–84

    PubMed  Google Scholar 

  48. Faraone SV, Biederman J, Monuteaux M, et al. Long-term effects of extended-release mixed amphetamine salts treatment of attention-deficit/hyperactivity disorder on growth. J Child Adolesc Psychopharmacol 2005; 15: 191–202

    PubMed  Google Scholar 

  49. Gale C, Oakley-Browne M. Generalised anxiety disorder. Clin Evid 2002; 8: 974–90

    Google Scholar 

  50. Geddes JR, Butler R. Depressive disorders. Am Fam Physician 2002; 65: 1395–7

    PubMed  Google Scholar 

  51. Pitschel-Walz G, Leucht S, Bauml J, et al. The effect of family interventions on relapse and rehospitalization in schizophrenia — a meta-analysis. Schizophr Bull 2001; 27: 73–92

    CAS  PubMed  Google Scholar 

  52. Biederman J, Spencer TJ, Newcorn JH, et al. Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data. Psychopharmacology (Berl) 2007; 190: 31–41

    CAS  Google Scholar 

  53. Bangs ME, Emslie GJ, Spencer TJ, et al. Efficacy and safety of atomoxetine in adolescents with attention-deficit/ hyperactivity disorder and major depression. J Child Adolesc Psychopharmacol 2007; 17: 407–20

    PubMed  Google Scholar 

  54. Ghaemi SN, Martin A. Defining the boundaries of childhood bipolar disorder. Am J Psychiatry 2007; 164: 185–8

    PubMed  Google Scholar 

  55. Scheffer RE, Kowatch RA, Carmody T, et al. Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium. Am J Psychiatry 2005; 162: 58–64

    PubMed  Google Scholar 

  56. Scahill L, Pachler M. Treatment of hyperactivity in children with pervasive developmental disorders. J Child Adolesc Psychiatr Nurs 2007; 20: 59–62

    PubMed  Google Scholar 

  57. Research Units on Pediatric Psychopharmacology Autism Network. Randomized, controlled, crossover trial of methyphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 2005; 62: 1266–74

    Google Scholar 

  58. Spencer TJ, Sallee FR, Gilbert DL, et al. Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome. J Atten Disord 2008; 11: 470–81

    PubMed  Google Scholar 

  59. Wilens TE, Adamson J, Sgambati S, et al. Do individuals with ADHD self-medicate with cigarettes and substances of abuse? Results from a controlled family study of ADHD. Am J Addict 2007; 16Suppl. 1: 14–21

    PubMed  Google Scholar 

  60. Wilson JJ. ADHD and substance use disorders: developmental aspects and the impact of stimulant treatment. Am J Addict 2007; 16Suppl. 1: 5–11

    PubMed  Google Scholar 

  61. Biederman J, Monuteaux MC, Spencer T, et al. Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled10-year follow-up study. Am J Psychiatry 2008; 165: 597–603

    PubMed  Google Scholar 

  62. US Food and Drug Administration. FDA asks attention-deficit hyperactivity disorder (ADHD) drug manufacturers to develop patient medication guides [online]. Available from URL: http://www.fda.gov/cder/drug/infopage/ADHD/default.htm [Accessed 2009 Feb 9]

  63. US Food and Drug Administration. FDA directs ADHD drug manufacturers to notify patients about cardiovascular adverse events and psychiatric adverse events [online]. Available from URL: http://www.fda.gov/bbs/topics/NEWS/2007/NEW01568.html [Accessed 2009 Feb 9]

  64. Eli Lilly and Company. Strattera PI. 2007 (Data on file)

  65. Stein MA. Unravelling sleep problems in treated and untreated children with ADHD. J Child Adolesc Psycho-pharmacol 1999; 9: 157–68

    CAS  Google Scholar 

  66. Findling RL, Bukstein OG, Melmed RD, et al. A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2008; e1-11

  67. Kratochvil CJ, Wilens TE, Greenhill LL, et al. Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006; 45: 919–27

    PubMed  Google Scholar 

  68. Faraone S, Biederman J, Morley C, et al. Effects of stimulants on height and weight: a review of literature. J Am Acad Child Adolesc Psychiatry 2008; 47: 1–16

    PubMed  Google Scholar 

  69. Swanson JM, Elliott GR, Greenhill LL, et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry 2007; 46: 1015–27

    PubMed  Google Scholar 

  70. Swanson J, Arnold LE, Kraemer H, et al. Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment Study of Children With ADHD (MTA): part I: executive summary. J Atten Disord 2008; 12: 4–14

    PubMed  Google Scholar 

  71. Swanson J, Arnold LE, Kraemer H, et al. Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment Study of children With ADHD (MTA): part II: supporting details. J Atten Disord 2008; 12: 15–43

    PubMed  Google Scholar 

  72. Spencer TJ, Newcorn JH, Kratochvil CJ, et al. Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit/hyperactivity disorder. Pediatrics 2005; 116: e74–80

    PubMed  Google Scholar 

  73. Baptista-Neto L, Dodds A, Rao S, et al. An expert opinion on methylphenidate treatment for attention deficit hyperactivity disorder in pediatric patients with epilepsy. Expert Opin Investig Drugs 2008; 17: 77–84

    CAS  PubMed  Google Scholar 

  74. Torres AR, Whitney J, Gonzalez-Heydrich J. Attention-deficit/hyperactivity disorder in pediatric patients with epilepsy: review of pharmacological treatment. Epilepsy Behav 2008; 12: 217–33

    PubMed  Google Scholar 

  75. Wernicke JF, Holdridge KC, Jin L, et al. Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine. Dev Med Child Neurol 2007; 49: 498–502

    PubMed  Google Scholar 

Download references

Acknowledgements

Sharon B. Wigal, PhD, has received consulting fees from Abbott Laboratories, McNeil Pharmaceutical, Inc., the National Institute of Mental Health and Shire Pharmaceuticals, Inc.; has received fees for non-CME services from McNeil Pharmaceutical, Inc., Novartis AG, Shire Pharmaceuticals, Inc. and UCB Pharma, Inc.; and has contracted research with Addrenex, Cephalon, Inc., Eli Lilly & Company, McNeil Pharmaceutical, Inc., the National Institute of Mental Health, Psychogenics and Shire Pharmaceuticals, Inc.

Author information

Affiliations

  1. Child Development Center, University of California Irvine, 19722 MacArthur Boulevard, Irvine, California, 92162, USA

    Sharon B. Wigal

Authors
  1. Sharon B. Wigal
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Wigal, S.B. Efficacy and Safety Limitations of Attention-Deficit Hyperactivity Disorder Pharmacotherapy in Children and Adults. CNS Drugs 23, 21–31 (2009). https://doi.org/10.2165/00023210-200923000-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200923000-00004

Keywords

  • Bupropion
  • Oppositional Defiant Disorder
  • ADHD Symptom
  • Atomoxetine
  • Modafinil